Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study

被引：24

作者：

Matulonis, Ursula A.

Shapira-Frommer, Ronnie

Santin, Alessandro

Lisyanskaya, Alla Sergeevua

Pignata, Sandro

Vergote, Ignace

Raspagliesi, Francesco

Sonke, Gabe S.

Birrer, Michael

Provencher, Diane M.

Sehouli, Jalid

Colombo, Nicoletta

Gonzalez-Martin, Antonio

Oaknin, Ana

Ottevanger, P. B.

Rudaitis, Vilius

Katchar, Kia

Wang, Zhen

Ruman, Jane

Ledermann, Jonathan A.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Sheba Med Ctr, Ramat Gan, Israel

[3] Yale Univ, Sch Med, New Haven, CT USA

[4] St Petersburg City Oncol Hosp, St Petersburg, Russia

[5] NCI Naples, Naples, Italy

[6] Univ Hosp Leuven, Leuven, Belgium

[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] Netherlands Canc Inst, Amsterdam, Netherlands

[9] BOOG Study Ctr, Amsterdam, Netherlands

[10] Univ Alabama Birmingham, Birmingham, AL USA

[11] Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada

[12] Charite Med Univ Berlin, Berlin, Germany

[13] Univ Milano Bicocca, Milan, Italy

[14] European Inst Oncol, Milan, Italy

[15] Clin Univ Navarra, MD Anderson Int Espana, Madrid, Spain

[16] Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[17] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[18] Vilnius Univ, Inst Clin Med, Vilnius, Lithuania

[19] Merck Co Inc, Kenilworth, NJ USA

[20] UCL, Canc Inst, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.5511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5511

引用

页数：1